Kavli Affiliate: Denis Wirtzr
| Authors:Adrian C. Johnston, Gretchen M. Alicea, Cameron C. Lee, Payal V. Patel, Eban A. Hanna, Eduarda Vaz, Andre Forjaz, Zeqi Wan, Praful R. Nair, Yeongseo Lim, Tina Chen, Wenxuan Du, Dongjoo Kim, Tushar D. Nichakawade, Vito W. Rebecca, Challice L. Bonifant, Rong Fan, Ashley L. Kiemen, Pei-Hsun Wu and Denis Wirtz
| Summary:
Chimeric antigen receptor (CAR) T cells express antigen-specific synthetic receptors, which upon binding to cancer cells, elicit T cell anti-tumor responses. CAR T cell therapy has enjoyed success in the clinic for hematological cancer indications, giving rise to decade-long remissions in some cases. However, CAR T therapy for patients with solid tumors has not seen similar successes. Solid tumors constitute 90% of adult human cancers, representing an enormous unmet clinical need, ripe for new cell therapies. Current approaches do not solve the central problem of limited ability of therapeutic cells to migrate through the stromal matrix. We discover that T cells at low and high density display low– and high-migration phenotypes, respectively. The highly migratory phenotype is mediated by a paracrine pathway from a group of self-produced inflammatory cytokines that include IL5, TNFα, IFNγ, and IL8. We exploit this finding to “lock-in” a highly migratory phenotype by developing and expressing receptors, which we call velocity receptors (VRs). VRs target these cytokines and signal through these cytokines’ cognate receptors to increase T cell motility and infiltrate lung, ovarian, and pancreatic tumors in large numbers and at doses for which control CAR T cells remain confined to the tumor periphery. In contrast to CAR therapy alone, VR-CAR T cells significantly attenuate tumor growth and extend overall survival. This work suggests that approaches to the design of immune cell receptors that focus on migration signaling will help current and future CAR cellular therapies to infiltrate deep into solid tumors.